VR Logo

Vera Therapeutics Inc. Class A (VERA) download report

Healthcare | Biotechnology & Pharma Research

Vera Therapeutics Inc. Class A (VERA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Get the Stocks!

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States.

IPO Date: 14-May-2021

Founder, Pres, CEO & Director: Dr. Marshall Fordyce M.D.

Chief Financial Officer: Mr. Sean P. Grant M.B.A.

Listing: NASDAQ: VERA

Country: United States

Headquarters: Brisbane, CA

Website: https://veratx.com

Key Facts

Market cap: $372.33 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-46.26 Mln

Cash: $150.94 Mln

Total Debt: $12.78 Mln

Insider's Holding: 8.44%

Liquidity: Low

52 Week range: $12.29 - 37.11

Shares outstanding: 26,769,200

Stock Performance

Time Period Vera Therapeutics Inc. Class A (VERA) S&P BSE Sensex* S&P Small-Cap 600*
YTD-50.15-8.97-18.40
1 month-16.17-3.38-8.42
3 months-41.37-7.93-14.06
1 Year-9.080.55-17.64
3 Years--10.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
AMCs: